title: Gastric acid secretion in Basenji dogs with immunoproliferative enteropathy.
abstract: Gastric acid secretion was studied in 13 Basenji dogs with immunoproliferative enteropathy. Considerable variation in the severity of gastritis and enteritis existed among dogs. Basenji dogs were categorized into two groups on the basis of postmortem gastric and intestinal histology (group I, gastritis and enteritis; group II, only enteritis). Pentagastrin-induced gastric acid secretory capacity was increased (P less than 0.002) in group II dogs as compared to healthy Beagle controls. Gastric acid secretory capacity of Basenji dogs with gastritis and enteritis (group I) was not different from that observed in control dogs. Basal serum gastrin concentrations and secretin-stimulated serum gastrin concentrations of either group of Basenji dogs did not differ from controls. On the basis of symptomatology, Basenji dogs with diarrhea had significantly increased basal and postsecretin stimulation gastrin concentrations (P = 0.01) when compared with asymptomatic Basenji or healthy control dogs. These findings support a potential role for altered gastric acid secretory capacity in the pathogenesis of immunoproliferative enteropathy of Basenji dogs. Results of the secretin stimulation studies support previous pathologic studies that failed to detect gastrin-secreting tumors. Incorporated into this investigation was a trial to determine whether the combination of oxymorphone and acepromazine could be used for acid secretory studies. Compared to pentobarbital, which has been frequently used for acid secretory studies in a research setting, the drug combination resulted in increased gastric fluid volumes, a comparative increase in acid secretion, and a rapid uneventful recovery. We conclude that the combination of oxymorphone and acepromazine provides an acceptable means of restraint in dogs undergoing acid secretory studies.
authors.affiliation: Department of Companion Animal and Special Species Medicine, College of Veterinary Medicine, North Carolina State University, Raleigh 27606.
authors.forename: E B
authors.initials: EB
authors.lastname: Breitschwerdt
authors.forename: N J
authors.initials: NJ
authors.lastname: MacLachlan
authors.forename: R A
authors.initials: RA
authors.lastname: Argenzio
authors.forename: S A
authors.initials: SA
authors.lastname: Hurlbert
authors.forename: C
authors.initials: C
authors.lastname: Babineau
authors.forename: E V
authors.initials: EV
authors.lastname: De Buysscher
mesh_terms: D000075:Acepromazine; D000758:Anesthesia / Q000662:veterinary; D000818:Animals; D001947:Breeding; D003967:Diarrhea / Q000378:metabolism / Q000662:veterinary; D004283:Dog Diseases / Q000378:metabolism*; D004285:Dogs; D004751:Enteritis / Q000378:metabolism / Q000662:veterinary; D005260:Female; D005744:Gastric Acid / Q000378:metabolism*; D005755:Gastrins / Q000097:blood; D005756:Gastritis / Q000378:metabolism / Q000662:veterinary; D007161:Immunoproliferative Small Intestinal Disease / Q000378:metabolism / Q000662:veterinary*; D008297:Male; D010111:Oxymorphone; D010424:Pentobarbital
chemical_list: D005755:Gastrins; D000075:Acepromazine; D010111:Oxymorphone; D010424:Pentobarbital